Discover the top 10 stock updates and analyst recommendations for November 11, featuring CoreWeave's revenue miss, Linde's upgrade, and Rocket Lab's soaring shares. Get insights into market trends and investment strategies!
The FDA has removed black box warnings on estrogen treatments for menopause, igniting a debate about the benefits and risks of hormone therapy. Dr. Marty Makary discusses the implications for women's health.
E.l.f. Beauty's acquisition of Hailey Bieber's Rhode is projected to add $200 million to annual sales, but disappointing guidance led to a 29% stock drop. Can Rhode save E.l.f. from its fiscal woes?
Norway's $2 trillion sovereign wealth fund has voted against Elon Musk's massive pay package at Tesla, defying management guidance amid a heated shareholder meeting. With Musk threatening to step down, tensions are rising as investors express concerns over executive compensation.
The American Academy of Pediatrics advises against the routine use of leucovorin for children with autism, citing insufficient evidence and urging caution amid rising parental demand for the treatment.
President Trump calls for urgent court clarification on SNAP funding, as millions face loss of food benefits during the government shutdown. Will the court's ruling come in time to help those in need?
Eli Lilly's stock surged 3.9% after an outstanding Q3 earnings report, surpassing analysts' expectations with $7.02 per share and $17.6 billion in sales. The company raised its yearly guidance, signaling strong growth potential.
Eli Lilly's third-quarter results exceeded estimates, driven by strong demand for Zepbound and Mounjaro. The company raised its revenue forecast, fueling a 5% rise in shares. Discover how Eli Lilly is maintaining its lead in the competitive obesity drug market.
Discover the good and bad news about the Social Security Fairness Act and its impact on your taxes! Learn how to navigate potential tax brackets and the IRS's guidance on lump sum payments.
A groundbreaking study shows that introducing peanuts to babies as early as 4 months can significantly reduce the risk of developing allergies. Health experts report a major decline in peanut allergy prevalence since revised guidelines were implemented.